<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762369</url>
  </required_header>
  <id_info>
    <org_study_id>171GLC18006</org_study_id>
    <nct_id>NCT03762369</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Efficacy and Safety of CKD-351</brief_title>
  <official_title>Multi Center, Randomized, Double-blind, Active Controlled, Parallel Design, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-351 in Primary Open Angle Glaucoma or Ocular Hypertension Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of CKD-351.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi center, Randomized, Double-blind, Active controlled, Parallel design, Phase 3 trial to
      evaluate the efficacy and safety of CKD-351 in primary open angle glaucoma or ocular
      hypertension patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 7, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean intraocular pressure at 12 weeks compared to baseline</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean intraocular pressure at 4 weeks, 8weeks compared to baseline</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intraocular pressure by measurement time</measure>
    <time_frame>4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>IOP variation by measurement time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessed by number of participants with treatment-related adverse events</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>CKD-351</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost+D930</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D930</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-351</intervention_name>
    <description>twice a day</description>
    <arm_group_label>CKD-351</arm_group_label>
    <other_name>Latanoprost+D930</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>once a day</description>
    <arm_group_label>Latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D930</intervention_name>
    <description>three times a day</description>
    <arm_group_label>CKD-351</arm_group_label>
    <arm_group_label>D930</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of CKD-351</intervention_name>
    <description>once a day</description>
    <arm_group_label>Latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of CKD-351</intervention_name>
    <description>twice a day</description>
    <arm_group_label>D930</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of D930</intervention_name>
    <description>three times a day</description>
    <arm_group_label>Latanoprost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than the age of 19 years old

          2. Subjects who has primary Open-Angle Glaucoma or Ocular Hypertension

          3. Subjects who sign on an informed consent form willingly

        Exclusion Criteria:

          1. Subjects with IOP(Intraocular Pressure) ≥35 mmHg at Visit 1 and Visit 2 (AM 09:00) at
             more than one eye

          2. Subjects with a maximum corrected visual acuity ≤ 0.3 in the selected evaluation eye
             at Visit 2

          3. Subjects who were diagnosed as below with monocular or both eye

               -  Acute or Chronic Closed-Angle Glaucoma

               -  Secondary Glaucoma

               -  Pseudoexfoliation Glaucoma

               -  Neovascular Glaucoma

               -  Aphakia

               -  Phacocyst capsular torn intraocular lens

          4. Subjects with significant eye symptoms/signs(Abscesses, diplopia) or severe visual
             field impairment(Mean Deviation ≥ -25dB)

          5. Subjects with severe dry eye syndrome or progressive retinal disease(Retinal
             degeneration, Diabetic retinopathy, Retinal detachment, Macular edema)

          6. Subjects with inflammatory/infectious eye disease and active eye disease within the
             last 3 months

          7. Subjects who have medical history following

               -  Subjects with significant history of ocular trauma during the last 6 months, or
                  who underwent surgical ophthalmic surgery

               -  Subjects who received topical or systemic steroids within the last 1 months

          8. Subjects who wore need to wear contact lenses during the study

          9. Women who are nursing, pregnant or planning pregnancy during the study

         10. Subjects with bronchial asthma or history

         11. Subjects with severe renal impairment (creatinine clearance &lt;30 ml / min at screening)
             or hyperchloremic acidosis

         12. Subjects who have received any other investigational product within 1 month prior to
             randomization

         13. Impossible subjects who participate in clinical trial by investigator's decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KiHo Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hosipital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KiHo Park</last_name>
    <phone>82-10-3458-3172</phone>
    <email>kihopark@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hosipital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>November 30, 2018</last_update_submitted>
  <last_update_submitted_qc>November 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Open-angle Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>CKD-351</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

